The mechanism of m6A modification in cardiovascular diseases: A systematic review

IF 9.4 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Genes & Diseases Pub Date : 2025-05-05 DOI:10.1016/j.gendis.2025.101672

Hongjiao Liu , Tao Song , Yan Huang

{"title":"The mechanism of m6A modification in cardiovascular diseases: A systematic review","authors":"Hongjiao Liu , Tao Song , Yan Huang","doi":"10.1016/j.gendis.2025.101672","DOIUrl":null,"url":null,"abstract":"<div><div>N6-methyladenosine (m6A) is the most prolific and conserved epigenetic modification of eukaryotic RNAs and is closely associated with the transcription, cleavage, translation, and degradation of target mRNAs. Cardiovascular disease (CVD) is the leading cause of death globally, with a significant research area focusing on understanding its pathogenesis and identifying effective therapeutic strategies. Recent advances in RNA methylation have revealed that m6A RNA modifications play a critical role in the initiation and progression of CVDs, potentially offering new insights into the development of these diseases. Interactions among various components influencing m6A modification levels regulate the effects of downstream targets, either by promoting or inhibiting CVD progression. This review connects the different types of CVDs and discusses the regulatory processes and intricate interactions between m6A methyltransferases and demethylases. We suggest that m6A RNA methylation could uncover potential targets for diagnosing and treating diseases, providing a clear view of how m6A modification affects CVDs and explaining the related molecular mechanisms and biological functions.</div></div>","PeriodicalId":12689,"journal":{"name":"Genes & Diseases","volume":"13 1","pages":"Article 101672"},"PeriodicalIF":9.4000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes & Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352304225001618","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

N6-methyladenosine (m6A) is the most prolific and conserved epigenetic modification of eukaryotic RNAs and is closely associated with the transcription, cleavage, translation, and degradation of target mRNAs. Cardiovascular disease (CVD) is the leading cause of death globally, with a significant research area focusing on understanding its pathogenesis and identifying effective therapeutic strategies. Recent advances in RNA methylation have revealed that m6A RNA modifications play a critical role in the initiation and progression of CVDs, potentially offering new insights into the development of these diseases. Interactions among various components influencing m6A modification levels regulate the effects of downstream targets, either by promoting or inhibiting CVD progression. This review connects the different types of CVDs and discusses the regulatory processes and intricate interactions between m6A methyltransferases and demethylases. We suggest that m6A RNA methylation could uncover potential targets for diagnosing and treating diseases, providing a clear view of how m6A modification affects CVDs and explaining the related molecular mechanisms and biological functions.

查看原文本刊更多论文

心血管疾病中m6A修饰的机制：系统综述

n6 -甲基腺苷（m6A）是真核rna中最高产、最保守的表观遗传修饰，与靶mrna的转录、切割、翻译和降解密切相关。心血管疾病（CVD）是全球死亡的主要原因，其发病机制和有效治疗策略是一个重要的研究领域。RNA甲基化的最新进展表明，m6A RNA修饰在心血管疾病的发生和发展中起着关键作用，可能为这些疾病的发展提供新的见解。影响m6A修饰水平的各种成分之间的相互作用通过促进或抑制CVD进展来调节下游靶标的作用。本文综述了不同类型的心血管疾病，并讨论了m6A甲基转移酶和去甲基化酶之间的调控过程和复杂的相互作用。我们认为m6A RNA甲基化可以发现疾病诊断和治疗的潜在靶点，为m6A修饰如何影响心血管疾病提供清晰的视角，并解释相关的分子机制和生物学功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genes & Diseases Multiple-

CiteScore

7.30

自引率

0.00%

发文量

347

审稿时长

49 days

期刊介绍： Genes & Diseases is an international journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch. Aims and Scopes Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis will be placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.